Objective: To concretely outline a process for selecting a total laboratory automation system that connects clinical chemistry, hematology, and coagulation analyzers and to serve as a reference for other laboratories.
and analytic system. In addition to selecting a laboratory automation system, we also wanted to use the process to ensure employee engagement in preparation for implementation. We evaluated a total of 5 vendors, of which 4 had analytic solutions for chemistry, hematology, and coagulation. Because this automation system connects the entire core laboratory-chemistry, hematology, and coagulation-we developed a multidisciplinary approach to ensure all aspects of this automation system were taken into consideration in the design of this system. In this article, we detail our evaluation process, including our evaluation matrix to benefit others who are considering total laboratory automation for their organization. Because each laboratory has different needs, 3 this article provides a framework for the evaluation process, not a recommendation on a specific vendor's solution. During our research, we found scant literature on how to select an automation system. [4] [5] [6] Further, there were no established steps on the selection process, especially for the total laboratory automation system. [4] [5] [6] Therefore, we believe the evaluation matrix and lessons learned in our process will be extremely valuable to other laboratories.
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Materials and Methods

Establishment of Goals, Vision, and Timeline
Establishing clear goals and timelines is a key component driving the decision making process. At the start of this project in March 2013, we were in the process of building a new core laboratory facility at our Danville, Pennsylvania, campus with an anticipated go-live date of June 2015. Our goal was to select a total laboratory automation system that connected chemistry, hematology, and coagulation for the new core laboratory and to allow enough time for implementation. We planned for just over a year on the selection process (March 2013 to April 2014) and another year for the capital request and implementation process (April 2014 to June 2015).
Our main goal was to improve efficiency, throughput, and reliability of sample processing, workstation delivery, and specimen retrieval for instrument-based assays.
Formation of a Committee
Our Laboratory Automation Committee (LAC) was composed of 5 subcommittees, each focused on unique aspects of the automation system. They were the (1) Laboratory Automation, (2) Chemistry Testing Platform, (3) Hematology Testing Platform, (4) Coagulation Testing Platform, and (5) Information Technology (IT)/Middleware subcommittees. This totaled 19 people in the committee. Given the impact of this automation system on both people and processes, the medical directors in the laboratory wanted to keep front-line technologists fully engaged in the process and treat them as decision makers. 7, 8 Our key committee members included technical specialists in different disciplines: hematology, coagulation, and chemistry. The main role for medical directors and supervisors was to lead and guide their teams in the evaluation process rather than to be the sole decision makers for the process.
In addition, we made a deliberate effort to ensure all shifts were involved in the process, as each shift faces different challenges and has unique needs. Although this automation system was intended for only one of our core laboratories in our multihospital system, the selection of this automation system would affect testing at the other hospitals and clinics because we strive for testing standardization in our hospital system. To maintain system perspective, we also included a technical supervisor from one of our other hospitals to join us in our selection process.
The main purpose of the committee was to choose vendors for evaluation; establish appropriate criteria for evaluation; evaluate instrumentations, automation systems, and middleware options; provide communication to laboratory staff on the selection process; and make a final recommendation to the laboratory medical executive committee. The committee decided to evaluate 5 vendors for the automation system. Except for one third-party vendor that could connect with any analytics of choice, the evaluation included not just the automation system but also the analytics and middleware. Given the amount of information each vendor provided for us to evaluate, the committee decided that it would be best to use a 2-phase approach in our selection process. We narrowed our selection from 5 to 2 vendors in the first phase, and then conducted an additional, more detailed evaluation on the final 2 vendors.
Phase I (March 2013 to November 2013)
Phase I of the selection process was kicked off by an official communication to all laboratory staff in the core laboratory automated testing area in an effort to engage technologists from all levels to participate in the process. The formal tools we used to gather information were request for information (RFI) process, site visits, and vendor presentations.
Request for Information-Team members from LAC were tasked to gather information relating to their disciplineslaboratory automation, chemistry testing platform, hematology testing platform, coagulation testing platform, and IT. The automation section asked for detailed information on track design, buffering units, STAT specimen handling capability, analytic instrumentations which can be connected with the automation line, [instruments that it connects with,] centrifuge design and capability, throughput, ongoing optimization support, service support, environmental requirements, IT (including middleware functionality), and development strategy. A complete list is provided in Table 1 .
The chemistry analyzer section requested detailed information on instrument design (STAT handling, clot detection, track design, automated rerun), test reagents (carryover, serum indices interference, lot-to-lot stability, FDA recalls, assay time, future tests in pipeline, etc.), service support, environmental requirements, and instrument software. A detailed list is provided in measuring range, extended reportable range, and reagent shelf life for each of the analytes in which we were interested.
Vendor Presentations-Each vendor was invited to provide on-site presentations to showcase their automation system and instrumentation to all members of the laboratory. Most vendors conducted multiple presentations to front-line technologists for all 3 shifts. In addition, they also gave in-depth presentations to committee members, as well as separate IT presentations focusing on the instrument software and middleware solution. Four of the 5 vendors also brought demonstration trucks on site for further demonstration. Technologists were encouraged to fill out evaluation forms to provide feedback to the selection committee.
Site Visits-One of the most valuable methodologies in our evaluation process was the site visit. 9 Our goal was to visit hospital laboratories that shared similar test volume and IT infrastructure-laboratory information system (LIS) and electronic health record (EHR) system. This helped us to evaluate whether a proposed solution could fit our laboratory. In some cases, visits to vendor vision centers/headquarters were arranged when the automation system was not available in a clinical laboratory.
A subset of the committee members was selected to visit each laboratory. technical leads interacted with the technical staff at the site visits, asking detailed technical questions to learn about the pros and cons of the system. In particular, the technical leads aimed to obtain practical clarification based on information previously received from vendors.
For the hospital laboratory visits, we exchanged hospital demographics and laboratory demographics in advance and tried to find sites that were most similar to our own in terms of the complexity of the processes. During these visits, our focus was to see the automation system in action and learn about the workflow. In addition, meetings with administrators, laboratory directors, technologists, and IT members were arranged to discuss their selection processes, add-on process, implementation strategy and change management. A list of our site visit questions is provided in Table 3 . All these discussions provided valuable insights. In particular, we talked not only about why the site selected the vendor currently in use, but also about the vendors that they decided not to use and why.
For visits to a vendor's vision center/headquarters, we provided them with scenarios that we would like to see on the automation lines so we could challenge the automation system with issues that we frequently encounter at our hospital laboratories.
Evaluation-To facilitate an unbiased evaluation of each vendor choices, the LAC developed a weighted decision matrix 10 to be used to score each vendor's option. For the automation system, our decision matrix included:
• Specimen loading options and sorting: Can the system handle STAT testing when there are bulk loading outreach and clinic work?
• Flexible track configuration and design: Can the system fit in our space? Can the configuration be changed in the future to allow for growth?
• Centrifugation options: Are the centrifuges easily programmable for different tube types? Are there enough centrifuges to prevent bottlenecks at centrifugation step?
• Aliquotter with pre-loaded consumables: Do we need to manually rack and load consumables like aliquot tubes and tips, or are they pre-loaded for convenience and time saving?
• Automated add-on retrieval process: How do we program the system to set up automated add-on retrieval process with our LIS and EHR?
• Compatibility with LIS and middleware: Is communication among automation lines, analytics, and LIS effective?
• Real time specimen tracking, error monitoring and longitudinal reporting: Is this available to facilitate timely troubleshooting and optimization?
• Acceptable tube types: What types can be used? Are the acceptable tube types compatible with what the hospitals and clinics currently use? What is the plan for microcollection tubes?
• Vendor support and service: How committed is the vendor to provide continual support beyond installation to assure optimization of the automation system?
• Does the system connect with our vendors of choice for hematology and coagulation instruments?
For the chemistry system, our decision matrix included:
• Test menus: Do the vendors offer tests of our interest? What about tests in the future pipeline? Is the testing methodology robust?
• Turnaround time: Is the assay time fast enough to deliver the needed turnaround time?
• Reagents: Is the quality of the reagents consistent? Is the analytical measuring range and dilution protocol defined by vendors? Is interference by hemolysis, lipemia, and icterus defined?
• Software/middleware: Does the instrument software and middleware provide values to enhance quality? Is it easy to use? Is there sufficient support to ensure effective use and integration of middleware?
• Maintenance: Is maintenance and reagent replenishment easy and fast? • Instrument: Is the instrument reliable? Does it have enough throughput? How does it ensure minimal carryover?
• Service/support: Who are the field support team? Where are they located? Are they committed to the service? Are they knowledgeable?
• Vendor track record: Does the company have good inventory management to ensure customers have reagents? Does the company respond to issues in a timely manner? Does the company disclose issues in a timely and open fashion?
• Fit for multilab system: Does the company have scalable instruments that fit our other clinical laboratories that are smaller than our core laboratory? Do those instruments share the same assay reagents to allow for standardization?
We prepared a comprehensive presentation to the laboratory medical executive committee, as well as a SWOT 11 (strengths, weaknesses, opportunities, threats) analysis of the 2 top-scoring vendors. The SWOT analysis provided a simple summary to senior management that could be shared with hospital leadership and used as part of the request for funding. This information was also shared with the entire laboratory staff for their feedback.
Once we finalized our top 2 vendor choices, the doctoral leaders of the LAC held a joint conference call with each vendor to communicate the decision in order to assure delivery of the message in a united and clear manner.
Phase II (December 2013-April 2014)
Phase II of our evaluation was to perform a side-by-side detailed comparison of the two vendors. A formal request for proposal (RFP) was sent to the vendor to determine how each would fit with our hospital laboratory space and workflow. In addition, we evaluated pricing for the final contract negotiation and capital request.
Request for Proposal-Our RFP was a standard hospital document created to ensure the automation system would meet the hospital system requirements (eg, security, IT, facility need) and to obtain financial information. In addition, we requested a proposal for automation system layout design and workflow design and analysis. We provided test volume and a detailed drawing of our available laboratory space and layout to the vendor to facilitate those activities.
Once the completed RFP was received from the vendors, we worked with them, along with our architect and facility managers, to refine the design of the instrument layout to ensure optimal workflow in our new laboratory. We also performed additional reference checks (via phone) and had additional unofficial discussions with colleagues to ask about their experience with the vendors. The latter helped ensure unbiased information.
We also met with each vendor to begin discussions on the implementation process.
Final Decision Matrix-We summarized our findings in a final presentation to our laboratory medical executive committee. Final decisions were based on cost, floor plan design, instrument footprint, workflow design, technology, analytical instruments that the automation line could connect with, service and support, future roadmap, growth potential, middleware, health system needs, and additional value-added items that the vendors provided.
Results
At the end of a 13-month intense evaluation process, our laboratory selected an automated system with connections to our vendor choice of hematology, coagulation, and chemistry testing platforms with automated sample storage and retrieval capability. Once the decision was made, our focus shifted to securing capital funding for the purchase and developing an implementation plan.
While the key outcome for this evaluation process was to select the automated system for our new core laboratory, an important secondary goal was to keep our employees engaged throughout the process. Frequent communications, including formal presentations and informal discussions, maintained staff involvement and ensured we received relevant feedback. It was vital to provide frequent updates as information became available and to alert employees as to what remained unresolved so that everyone felt part of this journey of transformation. 
Discussion
With our previous automation system, we had learned that physically connecting the track system with the analyzer was a relatively simple step compared to optimizing the system to maximize efficiency. In our previous experience, the optimization process occurred over years because of the lack of real-time data analysis. Data had to be collected and sent in to the vendor for analysis prior to a new intervention. Then, more data needed to be collected and sent to the vendor for analysis to determine if the new intervention worked. Therefore, an important consideration was to have the real-time data analysis capability and on-site field support to optimize the system in a timely fashion. In addition to real-time data analysis, IT and middleware are foundational to our successful operation of the automation system. IT and middleware control what tests are run and when, how the priority is set, how specimens are being routed, retrieved, and stored, etc. While it is impossible to evaluate all the IT details during evaluation process, we believe the key is to ensure the IT solution employed by the vendor is robust and collaborative, so that we can develop a solution or enhancement in a timely manner.
Although it was important to collect information from vendors regarding throughput, it was difficult to compare that data, because different vendors measure throughput differently.
Further, that measurement is not based on real laboratory scenarios. Therefore, it is important to discuss throughput with other users. Similarly, information collected from vendors should not be taken without validation. For example, it is one thing to state that the instrument works with your LIS; it is quite another to know how well (or poorly) it does. Therefore, the information collected from the vendors should be used as foundations for further evaluation during site visits and/or dialogues with other laboratories. We also asked our laboratory employees about their experience with various vendors, their instruments, and the service they provided.
We wanted to evaluate the next generation automation system that would serve our laboratory for the next 5 to 7 years. Some of the next-generation systems were not available in the United States at the time of our evaluation. It was challenging to gain feedback from other laboratories in that regard. However, we based much of our risk assessment on the vendor's track record and its industrial strategic partners. Ultimately, one has to assess whether the risk 12 outweighs the potential benefits of the new technology. For us, we chose the new technology over the known issues with the existing systems. We formed a strong partnership with our vendor to set up and optimize the system. We recognized that there could be challenges ahead as the system was brand new. Therefore, we allowed at least 6 months for the system operation to be stable. Having a realistic timeline with measurable goals and gains during the implementation phase helped keep the momentum and maintain the morale of the laboratory staff and administration during what seemed like a lengthy process.
Our tight evaluation timeline put some limitations on our opportunity to work with third-party vendors that could connect to any instrumentation. In theory, a third-party vendor would provide us with more flexibility for future expansion. However, it was clear to us that working with such a vendor would require more time than we could afford to fully evaluate our track design and assure proper connections during the early phase of evaluation.
As with many institutions, one of our biggest concerns was whether we would be able to secure funding for the automation and analytic system. The uncertainty of that and the upcoming laboratory move put a lot of stresses on our laboratory staff. That was also why it was so important to engage them throughout the process. In addition to sharing progresses, we also acknowledged the unknown and provided updates as information became available. This enhanced transparency, which reduced staff anxiety and promoted a true sense of working together.
Conclusion
Selecting an automated solution for multiple analytics is a complicated and time-consuming process; however, from our experience, setting clear goals and engaging the frontline staff were vital components for our success. It is important to define realistic goals and priorities in order to move the process forward. Because the process can be lengthy, especially the vendor negotiation phase and the internal funding-request process, a clear timeline must be set with all involved parties (finance, purchasing/contracting department, hospital administrators, etc.). Engaging front-line medical technologists in the evaluation process is critical to success in the selection and implementation process because they truly understand the workflow and the issues. Involving them in the evaluation process also helps improve employee engagement and paves the way for managing the change that must occur with the new automation system.
As with most laboratory instrumentation, a perfect solution is rare for an automation system. Therefore, understanding the limitation of the system is as important as knowing the capability to mitigate risk and safeguard a smooth implementation. The laboratory staff should meet key team members from the vendors who will be implementing the instrumentation. This should include the application, service, and installation teams to discuss installation and validation plans, an IT support person to discuss IT management, and a project manager to discuss overall timelines. This will give the laboratory confidence in how the vendor will carry out the implementation and support of the instrumentation installation. LM
